Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Raw Materials (2017 - 2024)

China Pharma Holdings' Raw Materials history spans 8 years, with the latest figure at $869820.0 for Q3 2024.

  • For Q3 2024, Raw Materials fell 53.69% year-over-year to $869820.0; the TTM value through Sep 2024 reached $869820.0, down 53.69%, while the annual FY2023 figure was $1.8 million, 0.52% up from the prior year.
  • Raw Materials reached $869820.0 in Q3 2024 per CPHI's latest filing, down from $1.2 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $2.2 million in Q1 2023 to a low of $869820.0 in Q3 2024.
  • Average Raw Materials over 5 years is $1.8 million, with a median of $1.8 million recorded in 2021.
  • Peak YoY movement for Raw Materials: rose 20.5% in 2023, then plummeted 53.69% in 2024.
  • A 5-year view of Raw Materials shows it stood at $2.1 million in 2020, then fell by 11.63% to $1.8 million in 2021, then changed by 0.0% to $1.8 million in 2022, then rose by 0.52% to $1.8 million in 2023, then crashed by 52.96% to $869820.0 in 2024.
  • Per Business Quant, the three most recent readings for CPHI's Raw Materials are $869820.0 (Q3 2024), $1.2 million (Q2 2024), and $1.7 million (Q1 2024).